Iraq vs Sao Tome and Principe: Prevalence rate of hypertension in women aged 30-79
Iraq
47.7
in 2019
Sao Tome and Principe
48
in 2019
Iraq rank
8th
Sao Tome and Principe rank
5th
Prevalence rate of hypertension in women aged 30-79 over time
- Iraq
- Sao Tome and Principe
How they compare
Sao Tome and Principe currently reports 48 against 47.7 in Iraq, a difference of 0.3.
The two have swapped places 3 times across 30 shared years of data; in 1990 it was Iraq ahead.
Iraq ranks 8th and Sao Tome and Principe ranks 5th of 195 countries.
Iraq has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Iraq | Sao Tome and Principe | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 45.37 | 43.18 | 2.19 | Iraq |
| 2000s | 47.05 | 46.21 | 0.84 | Iraq |
| 2010s | 47.9 | 47.85 | 0.05 | Iraq |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence rate of hypertension in women aged 30-79, Iraq or Sao Tome and Principe?
- Sao Tome and Principe, at 48 against 47.7 in Iraq as of 2019.
- What is the difference in prevalence rate of hypertension in women aged 30-79 between Iraq and Sao Tome and Principe?
- 0.3, with Sao Tome and Principe ahead.
- How many years of comparable data are there for Iraq and Sao Tome and Principe?
- 30 years are reported by both, from 1990 to 2019.
- How do Iraq and Sao Tome and Principe rank globally for prevalence rate of hypertension in women aged 30-79?
- Iraq ranks 8th and Sao Tome and Principe ranks 5th of 195 countries.
- Where does this data come from?
- World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data, published as Prevalence rate of hypertension in women aged 30-79. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Estimated share of female population with hypertension, based on population representative surveys and statistical modeling. Hypertension is a risk factor for chronic complications, including cardiovascular disease, and premature death.